At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 264 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Erlotinib 150 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients
In Brief
A Phase 2 clinical trial evaluating Erlotinib for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 264 participants across 29 sites in 14 countries.
Detailed Summary
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesBelgium, Bulgaria, Estonia, France, Germany, Hong Kong, Ireland, Italy, Poland, Russia, Singapore, Spain, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
Primary CompletionJun 2009
First PostedMay 2016
TodayJul 2026
First PostedMay 17, 2016
Enrollment StartJul 1, 2005
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.1 years ago
Interventions
Erlotinibdrug
Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.